Scancell Holdings plc

Scancell Holdings plc

SCNLF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$119.51M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Scancell Holdings plcScancell Holdings plc-4.6-155%--0.9
$-0.15

Current Fair Value

113.1% downside

Overvalued by 113.1% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$119.51 Million
Enterprise Value$131.27 Million
Earnings per Share$-0.18
Beta0.74
Outstanding Shares103,923,100

Return

Return on Equity155.12%ROE
Return on Assets-290.59%
Return on Invested Capital151.43%

Valuation & Multiples

P/E Ratio-4.63P/E Ratio
PEG0.09PEG
Price to Sales-Price to Sales
Price to Book Ratio-1.15Price to Book Ratio
Enterprise Value to Revenue27.86
Enterprise Value to EBIT-4.48
Enterprise Value to Net Income-5
Total Debt to Enterprise0.13
Debt to Equity-0.88Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
October 23, 2026
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
February 4, 2027
EPS Estimate
-$0.12
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Scancell Holdings plc

60 employees
CEO: Phillip John L'Huillier

Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious di...